PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
Year: 2024
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: G. Ruiter, H.-Y. Tu, M.-J. Ahn, K. Yoh, J. Zugazagoitia, E. Smit, Y.-L. Wu, D. Planchard, B.-C. Cho, B. Wehler, Y. Zhao, U. von Wangenheim, M. Rohrbacher, B. Sadrolhefazi, G. Lin, Y. Yu, E. Nadal, J. Heymach
Institutions: The Netherlands Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Samsung Medical Center, Sungkyunkwan University, National Cancer Center Hospital East, Hospital Universitario 12 De Octubre, Leiden University Medical Center, Université Paris-Saclay, Institut Gustave Roussy, Yonsei Cancer Hospital, Universitätsklinikum Gießen und Marburg, Zhengzhou University, Henan Cancer Hospital, Boehringer Ingelheim (Germany), Boehringer Ingelheim (United States), Fujian Medical University, Fujian Provincial Cancer Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Institut Català d'Oncologia, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4403410403